A meta-analysis of two Gynecologic Oncology Group (GOG) clinical trials shows a clear long-term survival benefit for intraperitoneal (IP) therapy over intravenous (IV) treatment of ovarian cancer. The results were presented at the 2013 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Los Angeles.
A meta-analysis of two Gynecologic Oncology Group (GOG) clinical trials shows a clear long-term survival benefit for intraperitoneal (IP) therapy over intravenous (IV) treatment of ovarian cancer. The results were presented at the 2013 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Los Angeles.
The findings, based on data from GOG clinical trials 114 and 172, represented outcomes in 876 women with advanced ovarian cancer. GOG-114 randomized patients with optimally resected stage III ovarian cancer to IV cisplatin/paclitaxel or to IV carboplatin followed by IP cisplatin/paclitaxel. In COG-172, women with resected stage III ovarian cancer were randomized to therapy with IV paclitaxel followed by either IV cisplatin or IP cisplatin and IP paclitaxel.
The new analysis showed a benefit of IP over IV therapy that extended beyond 10 years, with median survival time for both trials at 10.7 years. Median survival was 61.8 months for IP therapy, versus 51.4 months for IV treatment (P=0.048). IP therapy was associated with a 17% decrease in risk of death (adjusted hazard ratio [AHR]=0.83, 85% CI, 0.71-0.97; P=0.02). Younger age, better performance status, non-clear cell/mucinous histology, low-grade histology, and microscopic disease all were predictive of improved survival after IP therapy.
IP therapy’s survival advantage was evident in women with both microscopic (IP vs IV: 65% vs 58%) and gross residual disease (IP vs IV: 44% vs 35%). The 5-year survival rate was 59% in those who completed 5 or 6 cycles of IP therapy, compared to 18% vs 33% with 1 or 2 vs 3 or 4 cycles, respectively (P<0.001). Younger patients and women with microscopic residual disease were more likely to complete 6 cycles.
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More